The agency is proposing that device manufacturers improve their testing to including larger, more diverse sample sizes.

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

All entries were placed in a draw for one free registration to the TCT meeting and two Platinum memberships for TCTMD.

The proportion of female speakers increased over time, but they remain underrepresented in procedural and other specialties.

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

New techniques and devices made headway in tough treatment scenarios, and guidelines stressed the need for collaborative care ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

The year saw much-anticipated data on the value of early TAVI vs surveillance, plus two new tricuspid device approvals.